AUTHORS
Qing Shi I, Certified Doctor, Yaohui Huang Jr2, Jiayin He3, Shu Cheng, MD4, Pengpeng Xu, MD5, Weili Zhao6, Li Wang III, MD7
AFFILIATIONS
1 Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics; National Research Center for Translational Medicine at Shanghai, Shanghai Ruijin Hospital; Shanghai Jiao Tong University School of Medicine, shanghai, China
2 Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics; National Research Center for Translational Medicine at Shanghai, Shanghai Ruijin Hospital; Shanghai Jiao Tong University School of Medicine, shanghai, China
3 Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics; National Research Center for Translational Medicine at Shanghai, Shanghai Ruijin Hospital; Shanghai Jiao Tong University School of Medicine, shanghai, China
4 Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics; National Research Center for Translational Medicine at Shanghai, Shanghai Ruijin Hospital; Shanghai Jiao Tong University School of Medicine, shanghai, China
5 Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics; National Research Center for Translational Medicine at Shanghai, Shanghai Ruijin Hospital; Shanghai Jiao Tong University School of Medicine, shanghai, China
6 Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics; National Research Center for Translational Medicine at Shanghai, Shanghai Ruijin Hospital; Shanghai Jiao Tong University School of Medicine, shanghai, China
7 Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics; National Research Center for Translational Medicine at Shanghai, Shanghai Ruijin Hospital; Shanghai Jiao Tong University School of Medicine, shanghai, China
ABSTRACT
Background: High-risk relapsed/refractory (R/R) mantle cell lymphoma (MCL)—defined by blastoid/pleomorphic histology, high Ki-67 proliferation index (≥30%), TP53 aberration (TP53 mutation and/or del(17p)), complex karyotype, high MCL International Prognostic Index (MIPI) score, or early progression after first-line therapy—carries a poor prognosis. Single-agent Bruton tyrosine kinase inhibitors (BTKi) provide limited durable benefit. Glofitamab, a CD20×CD3 T-cell engaging bispecific antibody, has shown high complete response (CR) rates as monotherapy in R/R MCL, including BTKi-exposed patients. Combining glofitamab with the BTKi orelabrutinib and the proteasome inhibitor bortezomib may deepen and broaden responses through complementary anti-tumor mechanisms. We report preliminary efficacy and safety data of this triplet regimen in high-risk R/R MCL.
Methods: This is a prospective, single-center, single-arm phase II study in high-risk R/R MCL (NCT06656221). Patients received obinutuzumab pretreatment on C1D1, glofitamab step-up dosing per recommended schedule (2.5 mg C1D8, 10 mg C1D15, then 30 mg every 3 weeks on C2–C12 D1), bortezomib 1.6 mg/m² (D1/D8/D15, C1–C12), and orelabrutinib 150 mg daily. The primary endpoint was investigator-assessed CR rate by FDG-PET adopting the 2014 Lugano criteria. Responses were assessed at scheduled protocol time points; best overall response was analyzed in the efficacy-evaluable population (≥1 post-baseline assessment). Adverse events were graded per CTCAE v5.0 and cytokine release syndrome (CRS) per ASTCT criteria.
Results: As of the July 2026 data cutoff (median follow-up 12.3 months), 20 high-risk R/R MCL patients were enrolled. Median age was 67 years (range 52–84), 8 (40%) ≥70 years, and 15 (75%) were male. The median prior treatment lines were 1 (range 1–4); 6 patients (30%) received ≥2 prior lines (1 patient with 4 prior lines including a BTKi), and 50% of patients were refractory to last-line therapy. Fifteen patients completed ≥6 cycles and were efficacy-evaluable. The best overall response (BOR) was CR in all 15/15 (100%), yielding a CR rate and objective response rate (ORR) of 100%. Responses were consistent across patients with 1 prior line and ≥2 prior lines. Despite limited follow-up, 12/15 patients remain in ongoing remission, while 3 patients subsequently developed progressive disease. Notably, all three progressing patients achieved remission after 2 cycles and demonstrated CD20 loss at disease progression, consistent with CD20 antigen escape. The triplet was generally tolerable. CRS commonly occurred (14/15, 93%), all grade 1–2 (4/15 grade 2) without grade ≥3 events. The most common grade 3–4 adverse events were neutropenia (9, 60%), thrombocytopenia (7, 47%), and infections (2, 13%). No treatment-related deaths were reported.
Conclusions: This glofitamab-based triplet achieves high CR rates with manageable toxicity in high-risk R/R MCL, regardless of prior treatment lines. Early remissions appear durable, and CD20 antigen escape is the predominant mechanism of treatment failure. Enrollment and extended follow-up are ongoing to evaluate response duration and progression-free survival, supporting further investigation of this combination.
DISCLOSURES
Li Wang III, MD: No relevant conflicts of interest to declare.